Cost of Revenue: Key Insights for AbbVie Inc. and Sarepta Therapeutics, Inc.

Cost of Revenue: A Tale of Two Biopharma Giants

In the ever-evolving landscape of biopharmaceuticals, understanding the cost of revenue is crucial for assessing a company's financial health. AbbVie Inc. and Sarepta Therapeutics, Inc. offer a fascinating contrast in this regard. From 2014 to 2023, AbbVie Inc. has seen a staggering 361% increase in its cost of revenue, peaking at $20.4 billion in 2023. This reflects its aggressive expansion and investment in research and development. In contrast, Sarepta Therapeutics, Inc. has experienced a more modest growth, with its cost of revenue increasing by approximately 60% over the same period, reaching $150 million in 2023. This disparity highlights the different scales and strategies of these companies. While AbbVie focuses on broadening its portfolio, Sarepta remains committed to niche markets, particularly in genetic medicine. This data underscores the diverse approaches within the biopharma industry, offering valuable insights for investors and analysts alike.